

Global Biosimilars Market Forecast to 2015

<https://marketpublishers.com/r/GD8B2976F43EN.html>

Date: February 2012

Pages: 140

Price: US\$ 1,500.00 (Single User License)

ID: GD8B2976F43EN

Abstracts

The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid position and is expected to evolve greatly from its current state. As per the estimations of our latest report, the global biosimilars market will grow at a CAGR of around 52% during 2010-2015. With the governments and private players worldwide stepping in the industry, the market shows bright prospects and immense opportunities to cash in on.

According to “Global Biosimilars Market Forecast to 2015”, the first-generation biosimilars currently dominate the market, and their second-generation is expected to grow stupendously in the future. Our report provides a thorough study of the biosimilars market, and its segmentation at the product and country level. We have carried out a detailed market-segmentation analysis in the study, which presents forecasts on the first-generation biosimilars. Key developments in each segment have also been highlighted in it to tell ‘what is going on’ in the market.

For key regulated and unregulated markets including the US, Europe, India, China and Korea, the geographic-segmentation has been included. Our research has studied the overall industry performance and key biosimilar products in the market, and found that patent expirations offer a huge potential to new market entrants. The recent industry activities have been tracked, and the regulatory scenario has been analyzed to provide an impartial picture of the industry to clients.

We have covered the key market players in different geographies, and provided in the report a look at their activities, recent developments and key biosimilar products. We observed that players such as Sandoz/Novartis AG, Hospira and Teva are the global market leaders. Overall, the report aims at providing complete information about the biosimilar industry to clients who are planning to enter the biosimilars market.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. BIOLOGICS MARKET OUTLOOK TO 2015

3.1 Market Size

3.2 Market Segmentation

3.3 Country Level Analysis

4. MARKET TRENDS & DRIVERS

4.1 Cancer Indications Driving the Biosimilar Race

4.2 Rising Business Alliances Aiding in Biosimilar Development

4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth

4.4 Biosimilar Players in US to Prefer BLA over Abbreviated Pathway

5. BIOSIMILARS MARKET OUTLOOK TO 2015

5.1 Market Size

5.2 Market Segmentation

5.2.1 Erythropoietin

5.2.1.1 Scientific Insight

5.2.1.2 Market Analysis

5.2.1.3 Recent Activities

5.2.2 Human Growth Hormone

5.2.2.1 Scientific Insight

5.2.2.2 Market Analysis

5.2.2.3 Recent Activities

5.2.3 G-CSF

5.2.3.1 Scientific Insight

5.2.3.2 Market Analysis

5.2.3.3 Recent Activities

5.2.4 Monoclonal Antibody

5.2.4.1 Scientific Insight

5.2.4.2 Market Analysis

5.2.4.3 Recent Activities

5.2.5 Human Insulin

5.2.5.1 Scientific Insight

5.2.5.2 Market Analysis

5.2.5.3 Recent Activities

5.2.6 Interferons

5.2.6.1 Scientific Insight

5.2.6.2 Market Analysis

6. MAJOR GEOGRAPHICAL MARKET

6.1 US

6.1.1 Market Analysis

6.1.2 Regulatory Analysis

6.1.3 Recent Activities

6.2 Europe

6.2.1 Market Analysis

6.2.2 Regulatory Analysis

6.2.3 Recent Activities

6.3 India

6.3.1 Market Analysis

6.3.2 Regulatory Analysis

6.3.3 Recent Activities

6.4 China

6.4.1 Market Analysis

6.4.2 Regulatory Analysis

6.4.3 Recent Activities

6.5 Korea

6.5.1 Market Analysis

6.5.2 Regulatory Analysis

6.5.3 Recent Activities

7. COMPETITIVE LANDSCAPE (KEY PRODUCTS AND RECENT ACTIVITIES)

7.1 US

7.1.1 Hospira

7.2 Europe

7.2.1 Stada Arzneimittel

7.2.2 Hexal AG

7.2.3 Ratiopharm GmbH

7.2.4 Sandoz GmbH

7.2.5 Bioton

7.3 India

7.3.1 Dr.Reddy's Labs (DRL)

7.3.2 Intas Pharmaceuticals Ltd.

7.3.3 Biocon Limited

7.3.4 Wockhardt Limited

7.3.5 Shantha Biotechnics Limited

7.3.6 Reliance Life Sciences

7.4 China

7.4.1 3 SBio Inc.

7.4.2 Beijing Tri-Prime

7.4.3 Beijing SL Pharmaceutical Co., Ltd.

7.4.4 Shandong Kexing Biological Products Co., Ltd

7.4.5 Hangzhou Jiuyuan Gene Engineering

7.5 Korea

7.5.1 LG Life Sciences

7.5.2 Celltrion Pharm Inc.

7.5.3 Dong-A Pharmaceutical Co., Ltd

7.6 Others

7.6.1 Teva

7.6.2 Cangene Corporation

7.6.3 Microbix Biosystems, Inc.

List Of Figures

LIST OF FIGURES

Figure 3-1: Global - Biologics Market (Billion US\$), 2010-2015

Figure 3-2: Global - Biologics Market by Segment (%), 2010

Figure 3-3: Global - Share of Country/Region in Biologics Market

Figure 5-1: Global - Biosimilars Market (Million US\$), 2010 & 2015

Figure 5-2: Global - Biosimilars Market by Key Segment (%), 2010

Figure 5-3: Global - Erythropoietin Biosimilars Market (Million US\$), 2010-2015

Figure 5-4: Global - HGH Biosimilars Market (Million US\$), 2010-2015

Figure 5-5: Global - G-CSF Biosimilars Market (Million US\$), 2010-2015

List Of Tables

LIST OF TABLES

Table 4-1: Global - Pipeline Biosimilar Products of Key Players against Cancer

Table 5-1: Global - Marketed EPO Biosimilar Products of Key Players

Table 5-2: Global - Pipeline EPO Biosimilar Products of Key Players

Table 5-3: Global - Marketed HGH Biosimilar Products of Key Players

Table 5-4: Global - Marketed G-CSF Biosimilar Products of Key Players

Table 5-5: Global - Pipeline G-CSF Biosimilar Products of Key Players

Table 5-6: Global - Marketed mAb Biosimilar Products of Key Players

Table 5-7: Global - Pipeline mAb Biosimilar Products of Key Players

Table 5-8: Global - Marketed Insulin Biosimilar Products of Key Players

Table 5-9: Global - Pipeline Insulin Biosimilar Products of Key Players

Table 5-10: Global - Marketed Interferon Biosimilar Products of Key Players

Table 5-11: Global - Pipeline Interferon Biosimilar Products of Key Players

Table 6-1: US - Annual Prescription Costs/Person for Key Biologics

Table 6-2: US - Patent Expiries of Key Biologics

Table 6-3: Europe - Approved Biosimilar Products (2010)

Table 6-4: Europe - Patent Expiries of Key Biologics

Table 6-5: India - Key Approved Biosimilar Products

Table 6-6: China - Key Approved Biosimilar Products

Table 6-7: Korea - Key Approved Biosimilar Products

Table 6-8: Korea - Key Biosimilar Products in Pipeline

Table 6-9: Korea - Patent Expiries of Key Biologics

I would like to order

Product name: Global Biosimilars Market Forecast to 2015

Product link: <https://marketpublishers.com/r/GD8B2976F43EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD8B2976F43EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970